Oncology

Benefits of larotrectinib in patients with tumors harboring NTRK fusions have been established, with new data showing health-related quality of life benefits with its use.

Patients with TRK fusion–positive central nervous system tumors were observed to have increased efficacy and safety when treated with larotrectinib at long-term follow-up.

Without regard for tumor histology, NRG1-positive cancers treated with zenocutuzumab experienced promising efficacy and acceptable safety.

Across 3 clinical trials, investigators continued to observe durable responses with larotrectinib, which showed the importance of NTRK gene fusion testing in patients with various cancer types.

A biologics license application for pegfilgrastim-pbbk was accepted by the FDA for use in patients experiencing neutropenia while receiving chemotherapy.

Findings from the phase 3 DeFi study indicated that treatment with nirogacestat met the trial’s end points in patients with progressing desmoid tumors.

Patients who are black had a longer overall survival after investment was made for public welfare programs concerning those with cancer.

Seribantumab has been granted fast track designation by the FDA for those who have positive locally advanced or metastatic solid tumors with NRG1 gene fusions.

In an interview with ONCOLOGY®, Megan May, PharmD, BCOP, offers a comprehensive review of real-world treatment considerations of dostarlimab as therapy for adult patients with recurrent or advanced solid tumors with deficient mismatch repair.

Matthew Krebs, MB, PhD, spoke about how subcutaneous amivantamab can best be utilized in future clinical trials.

Pembrolizumab has been approved by the European Commission in 5 indications of solid tumors that are microsatellite instability–high or deficient mismatch repair.

Matthew Krebs, MB, PhD spoke about efficacy of subcutaneous amivantamab observed in the phase 1 PALOMA trial for patients with solid tumors.

Stéphane Champiat, MD, PhD, spoke about the reasoning behind using the IL-2/IL-15 superagonist SOT101 and where the research is heading for patients with solid tumors.

Bevacizumab-maly was approved by the FDA across numerous cancer indications, becoming the third FDA-approved bevacizumab biosimilar.

Matthew Krebs, MB, PhD spoke about the reasoning for the phase 1 PALOMA trial in patients with solid tumors who received a subcutaneous formulation of amivantamab.

Results of the phase 2 AURELIO-03 trial show SOT101 plus PD-1 inhibition induced responses in patients with advanced solid tumors.

Stéphane Champiat, MD, PhD, spoke about the results of the AURELIO-03 trial with SOT101 and pembrolizumab for patients with advanced solid tumors.

Patients with advanced solid tumors experienced an increase in dose-dependent T-cell proliferation following treatment with MEDI5752.

The phase 1b/2 KontRASt-01 trial demonstrated a positive safety profile of JDQ443 for patients with KRAS G12C-mutant solid tumors.

Patients with solid malignancies may benefit from treatment with next-generation PARP inhibitor AZD5305, according to findings from the phase 1/2a PETRA study.

Acceptable efficacy and safety were elicited in patients with advanced solid tumors and high tumor mutational burden detectable in both blood and tissue samples with nivolumab/ipilimumab therapy.

Data regarding different dosing strategies of elimusertib for advanced solid tumors with ATM alterations and other DNA damage repair gene defects display early efficacy of the therapy.

Based on results from the EPIK-P1 trial, the FDA has granted accelerated approval to alpelisib for PIK3CA-related overgrowth spectrum.

Shilpa Gupta, MD, and Jason R. Brown, MD, PhD, discuss a recently published paper by Grivas et al. (2019) on the use of checkpoint inhibitors for maintenance therapy to prolong the benefits of frontline therapy while minimizing toxicity in solid tumors.

Patients with cancer are at a higher risk for adverse financial effects compared with those who have not been diagnosed.

Candice Roth, MSN, RN, CENP, spoke about how the electronic treatment pathways have evolved over time.

Maurie Markman, MD, sits down with CancerNetwork® to discuss proposed legislation that would put a time limit on how long drugs with an accelerated approval can stay on the market, and how that may negatively impact patients with cancer.

A phase 1 study of davoceticept and pembrolizumab for advanced malignancies received a partial clinical hold from the FDA following a patient death.

In recognition of Black History Month, key opinion leaders from the community oncology space and beyond speak to how organizations are working to diversify clinical cancer research and combat outcome disparities.

Women undergoing treatment with immunotherapy, targeted therapy, or chemotherapy in cancer clinical trials were at a significantly increased risk of severe adverse effects compared with men.